Nuvation Bio Inc 's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Nuvation Bio Inc 's ROA in the second quarter of 2026?
Nuvation Bio Inc recorded a cumulative net loss of $-150 million during 12 months ending in the second quarter of 2026, resulting in a negative return on assets (ROA) of -23.49%.

However, within the Healthcare sector 379 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2026 quarter, so far to 3526, from total ROA ranking in the first quarter of 2026 at 4361.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Total Assets Change	15.03 %	23.91 %	10.02 %	5.25 %	8.81 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-150	-146	-205	-217	-203
Return On Assets (TTM)	-23.49 %	-23.8 %	-35.04 %	-38.12 %	-36.04 %
NUVB's Total Ranking	# 3526	# 4361	# 3882	# 3887	# 4566
Total Assets (TTM) in million	745	610	595	602	647
Seq. Total Assets Change	22 %	2.59 %	-1.12 %	-7.06 %	31.42 %
Seq. Net Income Change	-	-	-	-	-

NUVB's 5 Years Annual ROA >> Back to NUVB Management Effectiveness >> Compare NUVB ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 138
Sector	# 380
Overall	# 3489

Return On Assets Statistics
High	Average	Low
-10.79 %	-35.05 %	-110.28 %
(Dec 31 2021)		(Mar 31 2025)

News about Nuvation Bio Inc Return on Assets ROA

Nuvation Bio Appoints Colleen Sjogren as Chief Commercial Officer to Drive Growth Strategy amidst Financial Challenges

In an effort to strengthen its commercial capabilities and drive growth amid financial challenges, Nuvation Bio Inc (NYSE: NUVB), a biopharmaceutical company specializing in addressing unmet needs in oncology, has appointed Colleen Sjogren as its Chief Commercial Officer. The company unveiled the news today, emphasizing Sjogren s role in overseeing Nuvation Bio s commercial strategy and operations, including marketing, sales, and market access.
The appointment of Sjogren comes at a critical juncture for Nuvation Bio, as the company has reported a cumulative net loss of $-83 million during the twelve months ending in the third quarter of 2023. This has resulted in a negative return on assets (ROA) of -12.74%, indicating financial difficulties that require immediate attention.

Nuvation Bio Strengthens Leadership with Addition of Seasoned Biotech Veteran, Dr. Robert Mashal, to its Board of Directors

Nuvation Bio Boosts Board of Directors with Addition of Dr. Robert Mashal
Nuvation Bio Inc., a leading biopharmaceutical company focused on addressing significant unmet needs in oncology with innovative therapeutic candidates, has announced the appointment of Dr. Robert Mashal to its Board of Directors. This exciting development comes as the company strives to further advance its groundbreaking solutions for cancer treatment.
Dr. Mashal brings extensive expertise and experience to Nuvation Bio s Board of Directors, making him a valuable asset to the company. As a seasoned veteran in the biotech industry, his insights and strategic guidance will contribute to the company s success in developing novel therapies to combat cancer-related challenges.

Financial Statements
Nuvation Bio Inc 's Assets	$ 745 million	NUVB's Balance sheet
Nuvation Bio Inc 's Income	$ -63 million	Quarterly NUVB's Income Statement
NUVB's Income by Division		See NUVB's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021
Y / Y Total Assets Change	10.02 %	-13.01 %	-7.54 %	-13.4 %	435.26 %
Total Assets in million	595	541	621	672	776
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-205	-568	-76	-104	-87
Annual Return On Assets	-34.4 %	-105.05 %	-12.2 %	-15.5 %	-11.19 %

NUVB's 5 Years Annual ROA >> Back to NUVB Management Effectiveness >> Compare NUVB ROA to its Competitors

More Return On Assets Ratios
NUVB's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
NUVB's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for NUVB's Competitors
Subscribers only: Roa for Nuvation Bio Inc 's Suppliers
Subscribers only: Return On Assets for NUVB's Customers

You may also want to know
NUVB's Roi	NUVB's Inventory Turnover Ratio	NUVB's Growth Rates	NUVB's Dividend Comparisons
	NUVB's Profitability Ratios	NUVB's Asset Turnover Ratio	NUVB's Dividend Growth
NUVB's Roe	NUVB's Valuation Ratios	NUVB's Financial Strength Ratios	NUVB's Dividend Payout Ratio

Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector

ROA

Date modified: 2026-09-26T07:39:24+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.